Flashcards · Module 13
🩸 Blood & Cancer (Geriatric Hematology & Oncology)
4 of 4 cards published · read by the site’s author on 17 November 2026
Unexplained Anemia of the Elderly (UAE): Is anemia ever "just old age"?
Needs clinical review
The Golden Rule:
Anemia is not just 'old age': it is a key indicator of underlying conditions, so look for a cause.
What is UAE?
In about one third of older adults with anemia no cause is found: this is Unexplained Anemia of the Elderly (UAE). A third have nutrient deficiency and a third chronic inflammation or kidney disease.
What Drives It? Inflammaging!
🧪 Chronic low-grade inflammation ("inflammaging")
🔒 Inflammation and iron: in older people, higher inflammatory markers go with anemia and low iron, but one large study found no rise in hepcidin.
🫘 Blunted Erythropoietin (EPO): Aging kidneys produce less EPO in response to hypoxia.
🧱 Marrow disorders: bone marrow failure syndromes are among the causes.
Clinical Impact:
Even mild anemia may substantially affect physical and cognitive capacity and quality of life.
Sources checked (3) · 15 November 2026
CHIP (Clonal Hematopoiesis of Indeterminate Potential): The silent plaque inflamer
Needs clinical review
What is CHIP?
Blood stem cells in bone marrow acquire leukemia-associated somatic mutations (most commonly DNMT3A, TET2, ASXL1, JAK2). These mutated stem cells clone themselves so that ≥2% of peripheral blood cells carry the mutation—without any leukemia, lymphoma, or abnormal blood counts.
How Common Is It?
Age <40: rare
Age 70–79: about 10% (9.5%)
Age 80–89: about 12%; 90 and over: about 18%
The Big Surprise (The Board Question!):
You'd think CHIP's main danger is leukemia: it does raise blood cancer risk (hazard ratio 11.1), but it also raises coronary heart disease (2.0) and ischemic stroke (2.6), and all-cause mortality (1.4).
Why CHIP Destroys Arteries:
In mice, Tet2-deficient macrophages switch on inflammatory chemokine and cytokine genes.
In mice, this accelerated atherosclerosis.
In people, CHIP was associated with nearly double the risk of coronary heart disease.
Ischemic stroke risk was also higher (hazard ratio 2.6).
Sources checked (2) · 15 November 2026
Myelodysplastic Syndromes (MDS): Bone marrow failure in older adults
Needs clinical review
The Disease in Plain English:
MDS are myeloid disorders with low blood counts (cytopenias), dysplastic cells in the bone marrow, and a risk of turning into acute myeloid leukemia.
Presentation:
An older adult (median age about 68 in one large series) presents with progressive fatigue, recurrent infections, or easy bruising. Lab: unexplained anemia or bi/pancytopenia.
How We Stratify Risk:
We use the IPSS-R (Revised International Prognostic Scoring System):
Marrow blast percentage
Cytogenetics (5 risk groups, from very good to very poor)
Depth of cytopenias (Hb, platelets, ANC)
Treatment Strategy:
| MDS Risk Group | Goal | Treatment |
|---|---|---|
| Lower-Risk MDS | Relieve symptoms & stop transfusions | • RBC transfusions + iron chelation • Erythropoietin (ESA) if serum EPO ≤500 mU/mL • Lenalidomide (lower-risk MDS with chromosome 5 changes) |
| Higher-Risk MDS | Prolong survival & delay AML | • Hypomethylating agents (azacitidine, decitabine): azacitidine improved survival over conventional care in the AZA-001 trial • Allogeneic stem cell transplant for selected patients |
Sources checked (3) · 15 November 2026
- Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management. (2026)
- Revised international prognostic scoring system for myelodysplastic syndromes. (2012)
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. (2009)
Chemotherapy Toxicity in Older Adults: Predicting it with the CARG score
Needs clinical review
Why Standard Oncology Tools Fail:
Older patients have more comorbidities and often a compromised performance status, which makes chemotherapy harder to give safely.
Geriatric assessment adds risk factors such as:
Reduced kidney function (creatinine clearance <34 mL/min)
Needing help to take medications
Multi-agent (combination) chemotherapy
A fall in the last 6 months
The danger: Grade 3–5 toxicity (severe, life-threatening or fatal).
The Solution: The CARG Toxicity Score
The Cancer and Aging Research Group (CARG) tool uses 11 validated geriatric variables:
Age ≥72
Cancer type (GI or GU)
Standard planned chemo dose
Multi-agent chemotherapy
Hemoglobin (<11 g/dL in men, <10 in women)
Creatinine Clearance (<34 mL/min)
Hearing impairment
History of falls in last 6 months
Takes medications without assistance (IADL)
Decreased social activities due to health
Ability to walk 1 block
Risk Categories:
Low Risk (0–5 pts): ~30% risk of severe toxicity
Intermediate (6–9 pts): ~52% risk
High Risk (10–19 pts): ~83% risk of severe, life-threatening or fatal toxicity